Xenon Pharmaceuticals stock holds firm as analysts stick to buy ratings
Published on 09/02/2026 at 15:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Xenon Pharmaceuticals Inc. (CA98420N1050) stock was recently quoted around 60.00 USD on NASDAQ as of September 2, 2026, leaving the share price below the latest average analyst target but broadly in line with the company’s recent earnings tone.
Analysts see upside versus current price
According to data compiled by MarketBeat, Xenon Pharmaceuticals currently carries an average rating of Buy with an average price target of 77.13 USD, implying a double digit percentage gap above the recent 60.00 USD level as of September 2, 2026.
The same MarketBeat overview states that sell side analysts expect Xenon Pharmaceuticals to post earnings per share of -4.73 USD for the current fiscal year, underlining that investors are paying for the company’s development pipeline rather than near term profitability.
Earnings loss narrows versus prior year
Recent commentary on Xenon’s latest quarterly figures highlights a loss of 1.11 USD per share that nevertheless came in better than the consensus forecast loss of 1.16 USD per share, a positive surprise of 0.05 USD per share for the period.InsiderTrades also notes that during the same quarter a year earlier, Xenon recorded a loss of 1.07 USD per share, meaning the latest result represents a 0.04 USD per share widening of the loss year on year even though it beat expectations.
In the broader context, earlier coverage on August 6, 2026 described how Xenon’s earnings update prompted traders to reassess the stock, with the shares quoted at 60.22 USD and the fiscal year EPS view at -4.73 USD at that time, matching the current analyst forecast.An earlier Ad Hoc News summary also pointed out that several banks adjusted their targets while retaining positive recommendations.
Price level and valuation context
Shares of Xenon Pharmaceuticals stock opened at 60.00 USD on the most recent trading day cited in the analyst overview, giving the company a market capitalization of about 5.8 billion USD as of early September 2026.The same InsiderTrades note places the opening price and market value in this range.
Earlier trading data around September 1, 2026 showed Xenon Pharmaceuticals at 60.22 USD with a 52 week range of 35.60 USD to 72.66 USD and a market capitalization of 5.82 billion USD, so the current price of roughly 60.00 USD leaves the stock comfortably above its 52 week low yet still below the 72.66 USD 12 month high.The previous Ad Hoc News profile highlighted these levels.
For investors, the combination of a 5.8 billion USD market value, an expected full year loss of 4.73 USD per share and an average target of 77.13 USD underscores that the valuation remains dependent on confidence in the company’s clinical programs rather than traditional earnings metrics.
More figures and reports on Xenon Pharmaceuticals
Investors who want to follow Xenon Pharmaceuticals stock more closely can find additional regulatory filings, earnings summaries and analyst updates in the dedicated topic overview.
Key product and pipeline focus
Xenon Pharmaceuticals is a neurology focused biotech company whose pipeline centers on therapies targeting epilepsy and other central nervous system disorders, and investor attention typically concentrates on progress in late stage candidates that could drive future revenue once approved.
Stock price snapshot
Xenon Pharmaceuticals stock was around 60.00 USD as of September 2, 2026 on NASDAQ, compared with a 52 week span from 35.60 USD to 72.66 USD, leaving the shares trading in the upper half of their one year range but still below the highs seen earlier in the year.
Xenon Pharmaceuticals stock facts
- Company: Xenon Pharmaceuticals Inc.
- ISIN: CA98420N1050
- Ticker: XENE
- Trading venue: NASDAQ
- Price (as of September 1, 2026): 60.22 USD
- Market capitalization: 5.82 billion USD (as of September 1, 2026)
- Sector / Industry: Biotechnology / Pharmaceuticals
- Index membership: NASDAQ Composite
